- recruitingPHASE1
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
This study is testing a new drug, NXP900, for people with advanced cancers like lung cancer or kidney cancer. It's a very early-stage trial to see if the drug is safe and what dose works best.
United States · United Kingdom - recruitingPHASE1
A Study of PYX-201 in Advanced Solid Tumors
This study is testing a new medicine, PYX-201, for people with advanced solid cancers. Doctors want to find the best dose and see if it shrinks tumours. It's an early-stage study to understand how safe and effective the medicine is.
United States · Belgium · Spain - recruitingPHASE2
A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)
This study looks at new ways to treat advanced cancers by matching specific drugs to changes found in a patient's tumour genes. It tests three different drugs – atezolizumab, futibatinib, and amivantamab – to see how well they shrink tumours in different groups of patients.
France · Germany · Italy - active not recruitingPHASE1, PHASE2
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
This study is testing a new drug, BT7480, alone and with an existing drug, nivolumab, for advanced cancers that have a specific marker called Nectin-4. We want to find the safest dose, understand side effects, and see how well it works.
United States · United Kingdom - active not recruitingPHASE1, PHASE2
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
This study is testing a new drug, BT8009, alone or with another drug called pembrolizumab, for people with advanced cancers. It aims to find a safe and effective dose, understand how the body handles it, and see how well it works against different cancer types.
United States · Canada · France - recruitingPHASE1, PHASE2
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
This study is testing a new medicine, Tulmimetostat, for people with advanced cancers like solid tumours and lymphomas. It's looking at how safe it is, any side effects, and if it helps to shrink tumours.
United States · France · Italy - recruitingPHASE1
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
This study is testing a new drug, LY4052031, for people with advanced cancers like bladder, breast, and lung cancer. It aims to see if the drug is safe, what dose works best, and if it helps shrink tumors. It's an early-stage study to gather important information.
United States · Australia · China - recruitingPHASE1, PHASE2
First in Human Study of T3P-Y058-739 (T3P)
This study is testing a new treatment, T3P, for advanced solid tumours. It's a first human trial, looking at how safe and effective T3P is, both alone and with another drug called pembrolizumab, in adults aged 18-74.
Spain · Switzerland · United Kingdom - recruitingPHASE1, PHASE2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
This study is testing a new drug, rezatapopt, for advanced cancers with a specific gene change (TP53 Y220C). It's also looking at rezatapopt with another drug, pembrolizumab, to see how safe and effective they are. It’s for people who have already had cancer treatment.
United States · Australia · France - active not recruitingPHASE1
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
This study is testing a new treatment called RP3, alone and with another drug called Nivolumab, for advanced cancers. It aims to find out if RP3 is safe and how much to give for future studies.
United States · France · Greece - ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2, First in Human Study of DCC-3116 as Monotherapy and in Combination With RAS/MAPK Pathway Inhibitors in Patients With Advanced or Metastatic Solid Tumors With RAS/MAPK Pathway Mutations
This study is testing a new medicine, DCC-3116, for people with advanced cancers. It will see how safe it is and how well it works, both on its own and when given with other established cancer drugs. This is an early-stage trial to find the best way to use this new treatment.
Germany · Italy · Spain - ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-1200 in Participants with Advanced Solid Tumors
This study is testing a new medicine called MK-1200 for people with advanced solid tumours. It aims to see how safe the drug is and if it helps shrink tumours. It's an early-stage study, combining two phases to learn about the drug's effects.
Spain · France · Italy - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A study to Evaluate AB308 in Combination with AB122 in Participants with Advanced Malignancies (ARC-12)
This early-stage study is testing a new combination of medicines, AB308 and AB122, for people with several types of advanced cancer, including blood cancers and solid tumours. It aims to see if the treatment is safe and how the body reacts to it.
Spain · Poland - recruitingPHASE1, PHASE2
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
This study is testing a new medicine called EP0031 for advanced cancers caused by problems with a gene called RET. It aims to see if EP0031 is safe, what side effects it causes, and how well it works, especially for a type of lung cancer called NSCLC.
United States · France · Germany - recruitingPHASE1
A Study of MGC026 in Participants With Advanced Solid Tumors
This study is testing a new medicine called MGC026 for people with advanced cancers that have come back or spread. Doctors want to see if it's safe, what side effects it causes, and if it can help slow down or shrink tumors.
United States · Australia · United Kingdom - recruitingPHASE2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
This study is looking into a new medicine, Tovorafenib, for children and young adults aged 6 months to 25 years in the UK. It focuses on those with specific types of brain tumours (low-grade glioma) or advanced solid tumours that have come back or gotten worse, especially if they have certain genetic changes.
United States · Australia · Canada - recruitingPHASE1, PHASE2
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
This study is testing a new treatment called BNT326, sometimes with other medicines, for people with advanced cancers. It aims to see if these treatments are safe, how well they work, and what dose is best.
United States · Australia · Belgium - recruitingPHASE2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
This study is looking at a new treatment called HER3-DXd for people with certain advanced solid tumours that haven't responded to other treatments. It aims to see how well it works and if it's safe for different types of cancer, like melanoma, lung cancer, and breast cancer.
United States · Australia · Belgium - active not recruitingPHASE1
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
This early-stage study is testing a new drug, MOMA-313, for advanced solid tumours, including prostate, breast, and pancreatic cancers. It aims to find a safe dose and see how it works, either alone or with another drug called Olaparib, in patients whose tumours have a specific genetic weakness.
United States · Spain · United Kingdom - active not recruitingPHASE1
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
This study is looking into a new medication called ALTA2618 for adults with certain advanced cancers that have a specific genetic change (AKT1 E17K mutation). The main goal is to check its safety and find the right dose.
United States · Australia · France - active not recruitingPHASE1
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
This study is testing a new drug, NXP800, for people with advanced cancers. It aims to find a safe dose and see how well it works, especially for certain types of ovarian cancer that have a specific genetic change called ARID1a mutation.
United States · United Kingdom - recruitingPHASE1
Anti-GD2 ADC M3554 in Advanced Solid Tumors
This study is looking into a new medicine called M3554 for people with certain types of advanced cancer (soft tissue sarcoma or a brain tumour called glioblastoma). It aims to find the right dose, check if it's safe, and see how well it works against the cancer.
United States · Belgium · France - recruitingPHASE1
Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
This study is testing a new medicine called lunresertib, by itself or with other medicines (RP-3500 or Debio 0123), for people with advanced solid tumours. It aims to see if they are safe, what dose works best, and if they help shrink tumours.
United States · Canada · Denmark